Literature DB >> 31712872

[Multiple recurrent retroperitoneal liposarcoma in a 66-year-old man].

I Niemetz1, J Faß2, M Wolf3.   

Abstract

In this article, the authors present the case of a 66-year-old man who was diagnosed with the first recurrence of his retroperitoneal liposarcoma 7 years after initial diagnosis. In the following 10 years, he needed a total of eight operations, chemotherapy, and radiotherapy because of another seven recurrences. This is the first report on a patient with eight recurrences of a retroperitoneal liposarcoma being in a relatively good general condition even 17 years after initial diagnosis.

Entities:  

Keywords:  Chemotherapy, adjuvant; Hemocolectomy; Neoplasms, connective and soft tissue; Quality of life; Retroperitoneal liposarcoma, recurrence

Mesh:

Year:  2020        PMID: 31712872     DOI: 10.1007/s00108-019-00701-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  6 in total

1.  Management of retroperitoneal liposarcoma: A case report and review of the literature.

Authors:  Wei-Dong Zhang; DA-Ren Liu; Ri-Sheng Que; Chuan-Biao Zhou; Chen-Ni Zhan; Jian-Gang Zhao; L I Chen
Journal:  Oncol Lett       Date:  2015-05-08       Impact factor: 2.967

2.  [Retroperitoneal sarcomas: diagnostic and therapy].

Authors:  I Gockel; K Oberholzer; U Gönner; S Mantai; T Junginger
Journal:  Zentralbl Chir       Date:  2006-06       Impact factor: 0.942

3.  Retroperitoneal sarcoma: 25 years of experience with aggressive surgical treatment at the Institute of Oncology, Ljubljana.

Authors:  Darja Erzen; Mojca Sencar; Janez Novak
Journal:  J Surg Oncol       Date:  2005-07-01       Impact factor: 3.454

4.  Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group.

Authors: 
Journal:  Ann Surg Oncol       Date:  2016-08-01       Impact factor: 5.344

5.  A retrospective, single-center cohort study on 65 patients with primary retroperitoneal liposarcoma.

Authors:  Yi-Xi Wu; Jun-Yan Liu; Jia-Jia Liu; Peng Yan; Bo Tang; You-Hong Cui; Yong-Liang Zhao; Yan Shi; Ying-Xue Hao; Pei-Wu Yu; Feng Qian
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

6.  Clinico-pathological data and prognostic factors in completely resected AJCC stage I-III liposarcomas.

Authors:  P H Nijhuis; P R Sars; B E Plaat; W M Molenaar; W J Sluiter; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2000-08       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.